Tags

Type your tag names separated by a space and hit enter

Soy isoflavones in the treatment of prostate cancer.
Nutr Cancer. 2003; 47(2):111-7.NC

Abstract

Epidemiological studies suggest an inverse association between soy intake and prostate cancer (Pca) risk. We have previously observed that soy isoflavone genistein induces apoptosis and inhibits growth of both androgen-sensitive and androgen-independent Pca cells in vitro. To determine the clinical effects of soy isoflavones on Pca we conducted a pilot study in patients with Pca who had rising serum prostate-specific antigen (PSA) levels. Patients with Pca were enrolled in the study if they had either newly diagnosed and untreated disease under watchful waiting with rising PSA (group I) or had increasing serum PSA following local therapy (group II) or while receiving hormone therapy (group III). The study intervention consisted of 100 mg of soy isoflavone (Novasoy) taken by mouth twice daily for a minimum of 3 or maximum of 6 mo. Forty-one patients were enrolled (4 in group I, 18 in group II, and 19 in group III) and had a median PSA level of 13.3 ng/ml. Thirty-nine patients could be assessed for response. Soy isoflavone supplementation was given for a median of 5.5 (range 0.8-6) mo per patient. Although there were no sustained decreases in PSA qualifying for a complete or partial response, stabilization of the PSA occurred in 83% of patients in hormone-sensitive (group II) and 35% of hormone-refractory (group III) patients. There was a decrease in the rate of the rise of serum PSA in the whole group (P = 0.01) with rates of rise decreasing from 14 to 6% in group II (P = 0.21) and from 31 to 9% in group III (P = 0.05) following the soy isoflavone intervention. Serum genistein and daidzein levels increased during supplementation from 0.11 to 0.65 microM (P = 0.00002) and from 0.11 to 0.51 microM (P = 0.00001), respectively. No significant changes were observed in serum levels of testosterone, IGF-1, IGFBP-3, or 5-OHmdU. These data suggest that soy isoflavones may benefit some patients with Pca.

Authors+Show Affiliations

Division of Hematology and Oncology, Wayne State University, Detroit, MI 48201, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15087261

Citation

Hussain, Maha, et al. "Soy Isoflavones in the Treatment of Prostate Cancer." Nutrition and Cancer, vol. 47, no. 2, 2003, pp. 111-7.
Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2003;47(2):111-7.
Hussain, M., Banerjee, M., Sarkar, F. H., Djuric, Z., Pollak, M. N., Doerge, D., Fontana, J., Chinni, S., Davis, J., Forman, J., Wood, D. P., & Kucuk, O. (2003). Soy isoflavones in the treatment of prostate cancer. Nutrition and Cancer, 47(2), 111-7.
Hussain M, et al. Soy Isoflavones in the Treatment of Prostate Cancer. Nutr Cancer. 2003;47(2):111-7. PubMed PMID: 15087261.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soy isoflavones in the treatment of prostate cancer. AU - Hussain,Maha, AU - Banerjee,Mousumi, AU - Sarkar,Fazlul H, AU - Djuric,Zora, AU - Pollak,Michael N, AU - Doerge,Daniel, AU - Fontana,Joseph, AU - Chinni,Sreenivasa, AU - Davis,Joanne, AU - Forman,Jeffrey, AU - Wood,David P, AU - Kucuk,Omer, PY - 2004/4/17/pubmed PY - 2004/12/24/medline PY - 2004/4/17/entrez SP - 111 EP - 7 JF - Nutrition and cancer JO - Nutr Cancer VL - 47 IS - 2 N2 - Epidemiological studies suggest an inverse association between soy intake and prostate cancer (Pca) risk. We have previously observed that soy isoflavone genistein induces apoptosis and inhibits growth of both androgen-sensitive and androgen-independent Pca cells in vitro. To determine the clinical effects of soy isoflavones on Pca we conducted a pilot study in patients with Pca who had rising serum prostate-specific antigen (PSA) levels. Patients with Pca were enrolled in the study if they had either newly diagnosed and untreated disease under watchful waiting with rising PSA (group I) or had increasing serum PSA following local therapy (group II) or while receiving hormone therapy (group III). The study intervention consisted of 100 mg of soy isoflavone (Novasoy) taken by mouth twice daily for a minimum of 3 or maximum of 6 mo. Forty-one patients were enrolled (4 in group I, 18 in group II, and 19 in group III) and had a median PSA level of 13.3 ng/ml. Thirty-nine patients could be assessed for response. Soy isoflavone supplementation was given for a median of 5.5 (range 0.8-6) mo per patient. Although there were no sustained decreases in PSA qualifying for a complete or partial response, stabilization of the PSA occurred in 83% of patients in hormone-sensitive (group II) and 35% of hormone-refractory (group III) patients. There was a decrease in the rate of the rise of serum PSA in the whole group (P = 0.01) with rates of rise decreasing from 14 to 6% in group II (P = 0.21) and from 31 to 9% in group III (P = 0.05) following the soy isoflavone intervention. Serum genistein and daidzein levels increased during supplementation from 0.11 to 0.65 microM (P = 0.00002) and from 0.11 to 0.51 microM (P = 0.00001), respectively. No significant changes were observed in serum levels of testosterone, IGF-1, IGFBP-3, or 5-OHmdU. These data suggest that soy isoflavones may benefit some patients with Pca. SN - 0163-5581 UR - https://www.unboundmedicine.com/medline/citation/15087261/Soy_isoflavones_in_the_treatment_of_prostate_cancer_ L2 - http://www.tandfonline.com/doi/full/10.1207/s15327914nc4702_1 DB - PRIME DP - Unbound Medicine ER -